Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

NCT ID: NCT00864942

Last Updated: 2015-03-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-02-28
• Study Completion Date: 2014-10-31

Brief Summary

This study is for subjects with a B-cell lymphoid malignancy (lymphoma) or chronic lymphocytic leukemia (CLL) that has come back after or did not get better with previous treatment. The purpose of this study is to find out the highest dose of lenalidomide that can be given together with bendamustine and rituximab. The study will also look what effects the combination of lenalidomide and bendamustine and the combination of lenalidomide, bendamustine and rituximab will have on patients and their disease.

Detailed Description

This is a Phase I, open-label, dose-escalation study of bendamustine and lenalidomide (BL) and also bendamustine,lenalidomide, and rituximab (BLR) in relapsed/refractory CLL and relapsed/refractory B-cell lymphomas. Phase I dose escalation will be done independently for the CLL and NHL groups. In addition, the study will be conducted in 2 parts. In part I of the study, the maximum tolerated dose of bendamustine and lenalidomide will be determined independently for the CLL and NHL groups. In part II of the study, CLL and NHL subjects will be enrolled at the MTD of BL determined in Part I for CLL and NHL and all subjects will receive rituximab. Part II of the study will determine the MTD of BLT independently for the NHL and CLL groups.

Conditions

Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BL-NHL

Bendamustine and lenalidomide for NHL

Group Type: EXPERIMENTAL

BL-NHL

Intervention Type: DRUG

Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.

BLR-CLL

Bendamustine, lenalidomide, rituximab for CLL

Group Type: EXPERIMENTAL

BLR-CLL

Intervention Type: DRUG

Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.

BLR-NHL

Bendamustine, lenalidomide, and rituximab for NHL

Group Type: EXPERIMENTAL

BLR-NHL

Intervention Type: DRUG

Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.

BL-CLL

bendamustine and lenalidomide in patients with CLL

Group Type: EXPERIMENTAL

bendamustine and lenalidomide

Intervention Type: DRUG

Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.

Interventions

bendamustine and lenalidomide

Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.

Intervention Type: DRUG

BL-NHL

Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.

Intervention Type: DRUG

BLR-CLL

Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.

Intervention Type: DRUG

BLR-NHL

Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.

Intervention Type: DRUG

Other Intervention Names

Bendamustine HCL; Treanda; Revlimid; Bendamustine HCL; Treanda; Revlimid; Bendamustine HCL; Treanda; Revlimid; Rituxan; Bendamustine HCL; Treanda; Revlimid; Rituxan

Eligibility Criteria

Inclusion Criteria

• Documented relapsed or refractory B-cell NHL; CD-20 positive tumor. Indolent NHL: follicular B-cell lymphoma, diffuse small lymphocytic lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, transformed aggressive lymphomas, mantle cell lymphoma and chronic lymphocytic leukemia
• Maximum of 6 prior chemotherapy regimens. Prior rituximab is allowed.
• Bidimensionally measurable disease
• ECOG performance status 0-2
• Absolute neutrophil count >/= 1000 and platelet count >/= 50,000
• Serum creatinine </= 1.5 mg/dL
• Adequate hepatic function
• Estimated life expectancy of at least 3 months
• All study participants must be registered into the mandatory RevAssist program and be willing and able to comply with the requirements of RevAssist
• Able to take aspirin 81 mg daily as prophylactic anticoagulation

Exclusion Criteria

• Chemotherapy or immunotherapy within 3 weeks prior to entering study or failure to recover from adverse events due to any agents administered previously
• Use of investigational agents within 28 days of study
• Hematopoietic growth factors within 14 days of study
• History of prior high dose chemotherapy with allogeneic stem cell support
• History of prior radioimmunotherapy </= 1 year
• Concurrent treatment with therapeutic doses of systemic steroids
• Pregnant or lactating female subjects
• Concurrent, active malignancy other than lymphoma or CLL
• Primary CNS lymphoma
• Patients with a prior diagnosis of lymphoma active in the CNS are eligible only if CNS has been treated, and they are neurologically stable with no progressive symptoms off steroids and anti-convulsants
• Serious infection, medical condition, or psychiatric condition that, in the opinion of the investigator, might interfere with the achievement of study objectives
• Hypersensitivity to murine proteins or to any component of rituximab
• Known positive for HIV or infectious hepatitis type C; hepatitis type B that is active and uncontrolled
• Hypersensitivity to mannitol
• Evidence of laboratory tumor lysis syndrome by Cairo-Bishop criteria
• Subject with recent thromboembolic event (deep vein thrombosis or pulmonary embolism) unless clinically stable and event occurred more than 2 weeks prior to enrollment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Celgene Corporation

INDUSTRY

Sponsor Role: collaborator

Cephalon

INDUSTRY

Sponsor Role: collaborator

Georgetown University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bruce D Cheson, MD

Role: PRINCIPAL_INVESTIGATOR

Georgetown University

Locations

Georgetown University Hospital/Lombardi Cancer Center

Washington D.C., District of Columbia, United States

Countries

United States

Other Identifiers

2008-186

Identifier Type: -

Identifier Source: secondary_id

RV-CLL-NHL-PI-356

Identifier Type: -

Identifier Source: org_study_id